NCT03787498 - A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 19, 2019

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions

Relapsed Acute Myeloid Leukemia (AML)Refractory Acute Myeloid Leukemia (AML)High-risk Myelodysplastic Syndrome (MDS)

Interventions

DRUG

PLX2853

Tablets

Trial Locations (6)

NewYork-Presbyterian / Weill Cornell Medical Center, New York

Sidney Kimmel Comprehensive Cancer At Johns Hopkins, Baltimore

Northside Hospital, Atlanta

Ohio State University Medical Center, Columbus

University of Texas MD Anderson Cancer Center, Houston

Oregon Health and Sciences University, Portland